Establishment Labs Holdings Inc.

NASDAQ•ESTA

執行長: Mr. Juan Jose Chacon Quiros

板塊: Healthcare

行業: Medical - Devices

上市日期: 2018-07-19

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

聯絡資訊

Building B15 and 25, Coyol Free Zone, Alajuela, Costa Rica

506-2434-2400

www.establishmentlabs.com

市值

$1.95B

本益比 (TTM)

-38.6

23.6

股息率

52周最高

$83.31

52周最低

$28.67

52周範圍

69%

排名59Top 87.6%

2.2

F-Score

改良版 Piotroski 分析

基於 9 年期基本面

疲弱 • 2.2 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2017-2025

財務儀表板

Q4 2025 數據

營業收入

$64.62M+0.00%

近4季度走勢

每股收益

-$0.09+0.00%

近4季度走勢

自由現金流

-$2.43M+0.00%

近4季度走勢

2025 Annual 財報亮點

核心亮點

Revenue Growth Post-Approval Revenue reached $211.1M USD, increasing 27.2% driven by US market penetration post-approval.

US Market Sales Surge US market sales reached $45.6M USD for the year, following September 2024 FDA approval.

Gross Margin Improvement Gross margin increased to 69.3% from 66.0% due to higher selling prices in the United States.

Net Loss Significantly Narrows Net loss significantly narrowed to $51.1M USD, an improvement from the $84.6M USD loss reported previously.

關注風險

Sole Silicone Supplier Risk Reliance on sole silicone supplier Avantor presents risk as they plan to not automatically renew the supply agreement.

Continued Operating Losses Company incurred losses to date; achieving profitability depends on Motiva Implants commercial success and scaling.

Rising Operating Expenses Operating expenses rose significantly, with SG&A increasing 18.1% to $165.1M USD, impacting cost control.

Implant Safety Scrutiny Negative publicity and safety concerns regarding breast implants could harm reputation and reduce overall market demand.

未來展望

Preservé US Market Expansion Preservé launch continues through 2025, targeting a full commercial launch in the United States expected in 2026.

Elevated R&D Spending R&D expenses remain elevated for the decade-long post-approval study and advancing new product pipeline initiatives.

New CEO Strategy Execution New CEO appointed in May 2025; focus remains on executing US strategy and long-term growth priorities.

Future Capital Requirements Future capital needs depend on market adoption rates and managing significant ongoing regulatory compliance costs.

同行對比

營業收入 (TTM)

AHCO

$2.84B

+7.4%

TDOC

$2.53B

-1.5%

IART

$1.64B

+1.5%

毛利率 (最新季度)

IMTX

100.0%

+0.0pp

ATAI

100.0%

+0.0pp

TSHA

94.5%

+0.0pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
SYRE	$3.87B	-142.7	-29.4%	0.0%
NEOG	$2.09B	-3.4	-29.0%	0.0%
ZYME	$2.00B	-25.1	-26.0%	5.3%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

16.0%

高速增長

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

現金流需要關注

深度研究

下次財報:2026年5月5日

每股收益:-

營業收入:-

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料